Nutrition to improve quality of life of IBS patient

Nutrition to improve quality of life of IBS patient

Aantal projecten

1

Organisatie onderdeel

WR-cap AF

Project code

AF16012

Primaire MMIP

Landbouw, Water, Voedsel>D. Gewaardeerd, gezond en veilig voedsel>D2. De consument, duurzame en gezonde voeding in een groene leefomgeving

Start datum

01/01/17

Eind datum

31/12/21

Samenvatting

Food that contributes to a better quality of life for people with an irritable bowel. That is the focus of this research project which thereby contributes directly to mission D of the KIA: healthy, safe and appreciated food.
Irritable bowel syndrome (IBS) is an illness that affects a large group of people. It is estimated that 10%-20% of the world's population suffers from some form of IBS, which decreases quality of life. Adequate treatment options are very limited at the moment. This is partly because of the heterogenous patient population and the complicated pathology, of which not all mechanisms are fully understood. IBS is a multi-factor illness in which the intestinal wall, the immune system, enteroendocrine cells, and the microbiota play an important role.
Gastroenterologists often hear from patients that changes to their diet have the most impact on reducing the symptoms of IBS. However, it is unclear whether this is the same for every subgroup of patients, what mechanism causes this, and what food has the most significant positive impact.

The three most important objectives of this research project are:
• Increasing the insights into the underlying mechanisms regarding the pathology of IBS and how food can influence this;
• Identifying (new) links between food, food components, and/or dietary patterns and a decrease of IBS symptoms, also specifically for subgroups of IBS patients;
• Developing and optimizing in vitro models which will serve as a screening tool for further research into food components and IBS symptoms.

The research is divided into 3 work packages (WP):
WP 1 focuses on development of in vitro models that mimic IBS-related symptoms with individual or combined cell cultures. These in vitro models will be used to screen food components provided by the industrial partners to identify candidate food components that can alleviate IBS symptoms.
In WP 2, the in vivo research (animal and human studies) is conducted to validate the above-mentioned in vitro models.
In WP3 we examine the dietary patterns of IBS patients and the possible changes to their diet that they have already implemented to alleviate their symptoms, and which of these we can correlate to the quality of life. We also look at changes in microbiota related to the severity of IBS complaints.
All work packages contribute to improving the understanding of the mechanisms behind the pathology of IBS.

Doel van het project

This project contributes directly to mission D of the KIA: healthy, safe and appreciated food through its focus on food that contributes to a better quality of life for people with IBS. Specifically, the project contributes to the priorities within MMIP D2 related to the role and efficacy of food and diet-related interventions in preventing and curing chronic diseases and improving gut health and quality of life in IBS patients by identifying dietary patterns and food or food components that can decrease symptoms. More indirectly, the knowledge developed within this project can contribute to help IBS patients as consumers to change their behavior, leading to improved management of IBS symptoms and a healthy diet.

Relatie met missie (Motivatie)

Irritable bowel syndrome (IBS) is an illness that affects a large group of people. It is estimated that 10%-20% of the world's population suffers from some form of IBS, which decreases quality of life. Limited treatment is available at the moment. Gastroenterologists often hear from patients that changes to their diet have the most impact on reducing the symptoms of IBS. However, it is unclear whether this is the same for every subgroup of patients, what mechanism causes this, and what food has the most significant positive impact. Therefore, the results of this project are important to better understand the IBS pathology in relation to food, diet and nutrition, and to develop screening tools and novel food components that can speed up the development of innovative nutritional solutions.

Geplande acties

Deliverable 1: In vitro models - analyse compounds for their effects on the Caco-2 barrier integrity. Month 12.
Milestone 1.1 Measure Caco-2 barrier integrity by TEER and FD4/HRP and/or LPS translocation following exposure to compounds and/or challenge with serotonin and LPS. Month 6.
Milestone 1.2 Analyse Caco-2 gene expression responses to exposure to compounds. Month 12.

Deliverable 2: In vitro models - analyze compounds for their (indirect) effects on CRH-induced tryptase and histamine release by mast cells. Month 12.
Milestone 2.1 Establish mast cell culture in co-culture with Caco-2 and measure tryptase and histamine release in presence of CRH Month 6
Milestone 2.2 Determine tryptase and histamine release following exposure to compounds and CRH in a mast cell / Caco-2 co-culture setting. Month 12.
Milestone 2.3 Determine Caco-2 barrier integrity by TEER and FD4/HRP following exposure to compounds and CRH in a mast cell / Caco-2 co-culture setting. Month 12.

Deliverable 3: Questionnaire within IBS patient population. Month 18.
Milestone 3.1 Set up of a validated questionnaire. Month 6.
Milestone 3.2 Launch questionnaire within IBS patient population and data analysis. Month 18.

Deliverable 4: In vitro models - analyze compounds for their effects on serotonin production and secretion by enterochromaffin cells. Month 18.
Milestone 4.1 Establish Bon cell culture and measure serotonin release when stimulated with compounds and SCFA, tryptophan and CRH. Month 12.
Milestone 4.2 Determine serotonin release by Bon cells following exposure to compounds and CRH, SCFA or tryptophan. Month 18.

Deliverable 5: In vitro models - analyze compounds for their (indirect) effects on IFNγ-release by PBMCs. Month 18.
Milestone 5.1 Determine IFNγ-release by PBMCs following exposure to compounds and CRH or CRH-induced mast cell medium in a PBMC / Caco-2 co-culture setting. Month 18.
Milestone 5.2 Determine IFNγ-release and/or LPS translocation and/or SERT expression by Caco-2 following exposure to compounds and LPS and/or CRH or CRH-stimulated mast cell medium. Month 18.
Milestone 5.3 Determine IFNγ-release and/or LPS translocation and/or SERT expression by Caco-2 following exposure to compounds and LPS and/or serotonin or CRH-stimulated Bon cell medium. Month 18.

Deliverable 6: In vitro models - analyze effects of compounds on microbiota composition and SCFA production. Month 24.
Milestone 6.1 Measure changes in microbiota composition towards tryptophan producing strains following compound exposure (In vitro fermentation + SHIME model). Month 24.
Milestone 6.2 Analyse changes and final production of SCFAs by microbiota following compound exposure (In vitro fermentation + SHIME model). Month 24.

Deliverable 7: Perform mice experiment to further screen compounds for use in human study. Month 30.
Milestone 7.1 Write DEC protocol. Month 24.
Milestone 7.2 Perform animal study to measure relief of IBS symptoms. Month 30.

Deliverable 8: Perform human study to validate in vitro and mice trial data as pre-screenings tool. Month 42.
Milestone 8.1 Write METC protocol. Month 30.
Milestone 8.2 Perform human study to measure relief of IBS symptoms. Month 42.

Deliverable 9: Report on in vitro and mice trial results. Month 48.
Milestone 9 Write article on in vitro and mice trial results regarding compound-mediated relief of IBS symptoms. Month 48.

Deliverable 10: Report on human study results. Month 48.
Milestone 10 Write article on human study results. Month 48.

Terug

Geef een antwoord

Het e-mailadres wordt niet gepubliceerd.